GOSSAMER BIO INC (GOSS)
US38341P1021 - Common Stock
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023
GOSS stock results show that Gossamer Bio met analyst estimates for earnings per share the fourth quarter of 2023.
GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gossamer Bio (NASDAQ:GOSS) just reported results for the fourth quarter of 2023...
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
7 Micro-Cap Stocks That Could Majorly Surprise Investors
Although extremely small enterprises can be terrifyingly risky, these micro-cap stock surprises deserve a closer look.
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
Top Buys by Top Brass: COO/CFO Giraudo's $112.9K Bet on GOSS
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
Gossamer Bio COO/CFO purchases 200K common shares (NASDAQ:GOSS)
Gossamer Bio (NASDAQ:GOSS) disclosed on Tuesday its COO/CFO Bryan Giraudo bought 200K common shares at $0.5644/share for ~$112.9K.Shares of GOSS rose...
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs
Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023
Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update
Gossamer Bio falls after UBS downgrades (NASDAQ:GOSS)
Gossamer Bio (GOSS) fell ~4% Thursday noon after UBS downgraded the biopharmaceutical company, having said the next few years are more about execution.
Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results
Gossamer Bio to launch ~$212M private placement of securities (NASDAQ:GOSS)
Biopharmaceutical company Gossamer Bio (GOSS) said on Thursday that it is set to offer securities in an ~$212M private placement.
Gossamer Bio Announces $212 Million Private Placement Financing
Commit To Buy Gossamer Bio At $1, Earn 26.6% Annualized Using Options
Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference
